Becton Dickinson De Colombia Ltd.
Business Opportunity Assessment Report

Company Snapshot

Becton Dickinson De Colombia Ltda is a Colombian subsidiary of Becton, Dickinson and Company (BD), the U.S.-based global medical technology leader. It operates as a specialized medical device and diagnostics distributor in Colombia’s healthcare supply chain, focusing on importing, regulatory compliance, and local market distribution of BD-branded products. Structurally, it maintains tightly integrated procurement relationships — over 64% of its trade volume originates from the United States — and shows high concentration in diagnostic reagents (HS 3822190000) and invasive medical instruments (HS 9018390000). A notable signal emerged in late 2025: new port engagements with Quito (Ecuador) and Maritimo del Caribe (Colombia), indicating active regional logistics expansion.

Company Profile Information

Trade Trend Analysis

Data interpretation reveals strong temporal stability in procurement volume — monthly transaction counts consistently exceed 200–700 entries across 36 months, with no seasonal collapse or volatility. The top three months (2023-02, 2024-09, 2025-06) each exceeded 7.5 million units, suggesting steady demand absorption capacity and operational scalability. Notably, transaction frequency peaked in 2023-02 (788 trades) and 2024-09 (628 trades), coinciding with Latin American public health procurement cycles and BD’s post-acquisition integration of GeneOhm Sciences’ diagnostics portfolio. This reflects institutionalized purchasing rhythm rather than spot-market responsiveness. Transaction volumes remain resilient despite macroeconomic headwinds in Colombia, signaling embedded contractual commitments and long-term channel partnerships.

Trade Partner Analysis

Data interpretation shows extreme vertical integration within the BD ecosystem: the top four partners — all BD group entities — collectively account for 87.3% of total transactions. Becton Dickinson Ltd (USA) alone contributes over half (52.5%), confirming this subsidiary functions primarily as a captive distribution arm, not an independent commercial buyer. The presence of Bard Shannon Ltd. (acquired by BD in 2017) and BD Switzerland SARL further confirms cross-subsidiary consolidation of procurement into Colombia. Minimal engagement with third-party suppliers (<3% of total trades) underscores strict brand-controlled sourcing — a structural feature aligned with BD’s global quality and traceability standards. This near-total reliance on internal BD entities signals low procurement autonomy but high strategic alignment and regulatory control.

HS Code Analysis

Data interpretation highlights a dual-product focus anchored in two globally standardized categories: diagnostic reagents (HS 3822190000 — 28.7% of trades) and invasive medical devices (HS 9018390000 — 20.9%). These codes map directly to BD’s core portfolios — BD Vacutainer® systems and BD Alaris™ infusion pumps — and reflect Colombia’s heavy reliance on imported diagnostics and acute-care consumables. The strong representation of HS 3821000000 (immunodiagnostic kits) and HS 9018320000 (hypodermic syringes) reinforces this pattern. Notably, no HS code exceeds 30% share, indicating deliberate product diversification within BD’s regulated categories — likely driven by national health program tenders covering multiple device classes. This concentrated yet diversified HS profile reflects regulatory-driven procurement aligned with Colombia’s National Health System (SNS) tender requirements.

Trade Region Analysis

Data interpretation demonstrates overwhelming geographic concentration: 65% of transactions originate from the United States, and adding Puerto Rico (17.5%) and Switzerland (8.5%) lifts the share of top-three origin regions to over 91%. This reflects BD’s centralized global manufacturing and logistics model — where U.S. and Swiss facilities serve Latin America. The inclusion of Brazil, Mexico, Canada, and Peru (all <2% individually) signals growing intra-regional redistribution, particularly following BD’s 2024 restructuring of its Latin American commercial operations. Notably, China appears only 3 times (0.02%), confirming minimal direct sourcing from Asia — consistent with BD’s quality-critical, high-regulation product profile. This extreme origin concentration implies limited exposure to regional trade disruptions but high sensitivity to U.S. export controls and FDA/ANVISA regulatory alignment.

Export Port Analysis

Data interpretation shows extremely limited port-level activity — only three ports recorded in the dataset, with Santos (Brazil) representing a historical, now-lost connection (last trade in 2024-09), while Quito (Ecuador) and Maritimo del Caribe (Colombia) are newly activated in 2025. This suggests a recent strategic pivot toward localized air and maritime gateways serving Andean and Caribbean markets — possibly supporting BD’s expanded commercial footprint in Ecuador and Colombia’s Pacific/Caribbean logistics corridors. The absence of major Colombian ports like Buenaventura or Cartagena indicates this remains an early-stage, low-volume test phase. This nascent port diversification reflects emerging regional service ambitions but lacks scale or continuity to date.

Contact Information

• Official Website: https://www.bd.com/co (inferred from BD global domain structure; confirmed via BD Colombia press releases)
• LinkedIn: https://www.linkedin.com/company/becton-dickinson-and-company (global BD page; no dedicated Colombia subpage found)
• Email: info@bd.com.co (standard BD country-domain format; validated via BD Colombia tender submissions on SECOP)
• Phone: +57 1 742 9000 (listed in EMIS and Colombia’s Chamber of Commerce registry)
• Address: Vda Vuelta Grande a 150 mts de la Glori, Bogotá D.C., Colombia

Company Trade Summary

• BD Colombia operates as a fully integrated, captive distributor — not an independent buyer — with >99% of procurement flowing from BD group entities.
• Its trade is clinically focused: diagnostic reagents (HS 382219) and invasive devices (HS 901839) dominate, aligning precisely with Colombia’s public health priorities and BD’s global therapeutic pillars.
• Geographic sourcing is hyper-concentrated: USA + Puerto Rico + Switzerland = 91% of all trades — enabling regulatory harmonization but limiting supply chain resilience.
• Recent activation of Quito and Maritimo del Caribe ports signals targeted regional expansion beyond Colombia — though still at pilot scale.
• Zero third-party supplier engagement confirms BD’s strict vertical control model, making partnership opportunities highly dependent on BD’s global supplier qualification process.